RSPR Pharma AB today announced the initiation of a phase II clinical proof of concept trial of CRD007 in asthma patients not fully controlled by inhaled corticosteroids and long acting beta-agonists (ICS/LABA). The study is a randomized, placebo-controlled, double-blind multicenter trial involving up to 200 patients at 15 centers in 3 different countries.